Entera Bio Secures $6.6 Million in Private Placement, Extending Cash Runway through 2025
Jerusalem-based biopharmaceutical company, Entera Bio Ltd. (NASDAQ: ENTX), has successfully concluded a private placement offering on December 22, 2023, raising approximately $6.6 million in gross proceeds. The placement involved existing and new investors who purchased 7,916,879 units at a price of $0.835 per unit. This recent financing will significantly extend Entera’s cash runway, ensuring the company’s financial stability through 2025.
Entera Bio is recognized as a pioneer in the development of orally delivered peptides and therapeutic proteins. The company’s innovative oral drug delivery technology has the potential to revolutionize the pharmaceutical industry by offering non-invasive and patient-friendly alternatives to injectable medications.
The private placement involved the issuance and sale of units, with each unit comprising one ordinary share of Entera or one pre-funded warrant, as well as a five-year warrant. By securing this investment, the company can further advance its research and development programs, which involve the development of orally delivered therapeutics for various medical conditions.
The successful completion of the private placement reflects the confidence and support of both existing and new investors in Entera Bio’s potential to transform the field of drug delivery. The funds raised will be channeled toward advancing the company’s pipeline of peptide-based therapies, as well as for general corporate purposes.
With an extended cash runway through 2025, Entera Bio can continue to focus on accelerating the development of its product candidates, targeting diseases where oral drug delivery is advantageous over traditional injectable therapies. The company’s proprietary drug delivery technology enables the oral administration of peptide-based drugs, overcoming the limitations associated with protein degradation in the gastrointestinal tract.
Entera’s innovative platform has already demonstrated its potential through collaborations with leading pharmaceutical companies, including Amgen, allowing for the exploration of new treatment options. The ability to deliver peptides orally has the potential to enhance patient compliance, reduce healthcare costs, and improve treatment outcomes for various diseases, such as osteoporosis, inflammatory bowel disease, and anemia.
Furthermore, Entera Bio’s robust intellectual property portfolio provides a strong foundation for continued growth and development. The company has secured patents for its oral drug delivery platform, solidifying its competitive advantage in the field of pharmaceutical innovation.
As Entera Bio continues to make significant strides in the development of orally delivered peptides, the completion of the private placement signifies a major milestone in the company’s journey. This achievement not only enhances Entera Bio’s financial position but also reinforces its commitment to providing novel treatment options that can revolutionize patient care.
By securing $6.6 million in gross proceeds, Entera Bio has solidified its position as a key player in the biopharmaceutical industry. With an extended cash runway, the company is well-positioned to drive its research and development efforts, bringing groundbreaking orally delivered therapies to patients in need.
In conclusion, Entera Bio’s successful private placement marks a significant step forward for the company, demonstrating the market’s trust in its game-changing drug delivery technology. Entera remains committed to transforming the lives of patients through innovative, orally delivered therapeutics, and this recent financing reinforces its ability to deliver on that promise.
Comments